contezolid acefosamil + contezolid

**Contezolid acefosamil + contezolid** is a pharmaceutical combination that includes *contezolid acefosamil* (a prodrug of contezolid) and *contezolid* itself. Both belong to the oxazolidinone class of antibiotics targeting multidrug-resistant Gram-positive bacterial infections[1][2][3][4]. \n- **Contezolid acefosamil** (MRX-4) is an *O-acyl phosphoramidate* prodrug of contezolid, developed to improve aqueous solubility for intravenous administration[4]. Upon IV or oral administration, contezolid acefosamil is rapidly converted into the active drug contezolid in vivo[1][2][3][4]. \n- **Contezolid** is an active oxazolidinone antibiotic with a mechanism involving inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing formation of the initiation complex in bacterial translation. \n- The combination can facilitate sequential therapy, starting with intravenous contezolid acefosamil for hospitalized or severely ill patients, and switching to oral contezolid for continued outpatient care[1][2][3]. \n- Both forms demonstrate improved safety profiles with low incidence of hematological adverse events compared to older oxazolidinones like linezolid[1].

Other names

contezolid acefosamilcontezolid